ICE Symposium: Improving the Management of X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia with Novel Treatment Options
ICE Symposium: Improving the Management of X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia with Novel Treatment Options
Karl L. Insogna, MD, FACP
Ensign Professor of Medicine/Endocrinology
Director, Yale Bone Center
Associate Director, Yale Center for X-Linked Hypophosphatemia
Yale School of Medicine – Yale University
New Haven, Connecticut
Jill H. Simmons, MD
Professor of Pediatrics
Ian Burr Division of Pediatric Endocrinology and Metabolism
Director, Program for Pediatric Metabolic Bone Disorders
Vanderbilt University Medical Center
Nashville, Tennessee
Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Global Company.
For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.
This activity is designed for physicians, nurses, and physician assistants
After participating in this activity, learners should be better able to:
- Describe the pathophysiological mechanisms of XLH and TIO
- Evaluate the mechanisms, efficacy, and safety of agents approved for the treatment of XLH and TIO
- Develop personalized strategies for the long-term management of children and adults with XLH and TIO with ongoing disease monitoring and, when indicated, interdisciplinary clinical care
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: February 25, 2021
Expiration Date: February 25, 2022
Estimated Time to Complete: 1.00 hour
There is no fee associated with this activity.
NACCME would like to thank the following company who has supported "ICE Symposium: Improving the Management of X-Linked Hypophosphatemia and Tumor-Induced Osteomalacia with Novel Treatment Options" through educational grants and/or in-kind support: Ultragenyx
In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates this internet live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity awards 1.00 contact hour.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.00 contact hour.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
NACCME, LLC is an independent provider of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
In accordance with our disclosure policies, NACCME is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.
Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:
- Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
- any investigational, off-label, or non-FDA approved content or discussion
NACCME has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.
Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:
- All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
- Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.
FACULTY
The faculty has reported the following:
Dr. Insogna: Clinical Trials—Ultragenyx
Dr. Simmons: Research Grants—Ultragenyx
Dr. Jan De. Beur and Ms. Seaman have disclosed no relevant financial relationships with any commercial interests.
CLINICAL REVIEWER
Suzanne Jan de Beur, MD
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr. Jan De. Beur and Ms. Seaman have disclosed no relevant financial relationships with any commercial interests.
PLANNING COMMITTEE
Susie Seaman, NP, MSN, CWOCN (nurse planner)
Susie Seaman Wound Care Consulting
San Diego, CA
Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).
NACCME planners and staff include Damon Clark, Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers and Margie Stefan.
No NACCME planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).
North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2021 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers, Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.
